Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18

Key Points

• Regeneron has a “Moderate Buy” consensus rating from 24 analysts, with 14 buys and 10 holds. The average 12-month price target is $802.18.
• The company exceeded quarterly expectations, reporting $14.29 in earnings per share versus a $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year.
• Regeneron faces a potential competitive threat to its Eylea franchise after Kodiak Sciences reported positive Phase 3 results for longer-acting eye-drug candidates; meanwhile, institutional investors own 83.31% of REGN shares and insiders have recently sold stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-four brokerages that are presently covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $802.18.

Several research analysts have issued reports on the stock. Truist Financial increased their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a report on Friday, July 31st.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. The trade was a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Nuveen LLC boosted its stake in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $473,872,000. Bank of New York Mellon Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Finally, Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $323,249,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is collaborating with Biohaven on a clinical study combining Biohaven’s BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors. Enrollment in the combination cohort is underway, creating a potential long-term pipeline opportunity. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Positive Sentiment: Regeneron’s upcoming third-quarter earnings report is an important potential catalyst. The company recently delivered earnings and revenue above consensus expectations, and its shares continue to screen as a value candidate relative to some biotechnology peers. Should You Buy Regeneron Pharmaceuticals Stock Before October 30?
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and assigned a $737 price target, indicating limited near-term upside based on its current valuation assessment. Regeneron Rating Reaffirmed by Royal Bank of Canada
• Neutral Sentiment: Comparisons with Illumina and European drugmakers GSK and Sanofi highlight Regeneron’s valuation and earnings outlook, but these articles do not identify a new fundamental change specific to REGN. REGN or ILMN Value Comparison
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted, with both candidates meeting primary endpoints against Eylea in wet age-related macular degeneration. The potential for similar vision outcomes with approximately six-month dosing, compared with Eylea’s roughly eight-week schedule, raises a meaningful competitive threat to Eylea’s market share and future growth. Kodiak’s stock surged more than 170% on the news, intensifying pressure on REGN. Kodiak Positive Eye-Drug Study Data

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $750.51 on Wednesday. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $782.91 and a two-hundred day simple moving average of $720.82. The stock has a market capitalization of $77.27 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 1.47 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm posted $12.81 earnings per share. The business's revenue for the quarter was up 16.7% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.